Adaptive Biotechnologies Corp vs Fabrinet — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Fabrinet trades at $555 (market cap $18.84B). The key difference: Fabrinet is far larger — about 4.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals.
| ADPT | FN | |
|---|---|---|
Market Cap | $4.04B | $18.84B |
Sector | Health | Technology |
52-Week High | $25.45 | $746.47 |
52-Week Low | $12.30 | $277.04 |
Enterprise Value | $4.10B | $17.90B |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →